Abstract: The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4?-Ethynyl-2-fluoro-2?-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and/or the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC.

Abstract: An analysis system implements a particulate classification model trained as a convolutional neural network to assess sterile formulation quality. The system obtains micro flow imaging (MFI) data for a sterile formulation drug product, wherein the MFI data includes an image depicting a plurality of sub-visible particulates in the sterile formulation drug product. The system detects a plurality of features in the image, wherein each feature is bounded by a bounding box. The system performs preprocessing to determine and remove one or more of features to be artifacts based on characteristics of the features, wherein the remaining features are determined to be sub-visible particulates. The system applies a particulate classification model to each sub-visible particulate to determine a particulate classification label. The system determines a quality metric for the sterile formulation drug product based on a count of sub-visible particulates in each particulate classification label.

Abstract: In some embodiments, a reciprocal injection device includes a platform having a motor, a gearbox operatively coupled to the motor, an actuation slide driven by the motor, a pair of clamp fixtures for supporting two syringes, a pair of axially translatable syringe plunger fixtures, and an interface in communication with the platform and configured and arranged to actuate the motor.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.

Abstract: The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4?-Ethynyl-2-fluoro-2?-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and/or the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC.

Abstract: A resistance spot welding method of galvanized high-strength steel with good joint performance, in which three welding pulses are used within one spot welding schedule. The method includes applying a first welding pulse and a second welding pulse which are used for generating a nugget and suppressing the generation of liquid metal embrittlement (LME) cracks, respectively. The first welding pulse generates a nugget having a diameter of 3.75T1/2-4.25T1/2 in which T represents a plate thickness. The second welding pulse causes the nugget to grow at a rate less than a rate of growth during the first welding pulse. A third welding pulse, which is a tempering pulse, is applied for improving plasticity of a welding spot.

Abstract: The invention provides methods for producing crystalline an anti-PD-1 monoclonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant, comprising (1) mixing a solution comprising (a) the mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of: caffeine, theophylline, 2? deoxyguanosine-5?-monophosphate, a bioactive gibberellin, and a pharmaceutically acceptable salt of said bioactive gibberellin, to form a crystallization solution, (2) incubating the crystallization solution for a period of time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In specific embodiments, the PEG is PEG 3350 and the additive is caffeine. The invention also relates to the novel anti-human PD-1 mAb crystals produced by the methods described herein.

Abstract: Provided is a steel welding component having a steel welding blank with an aluminum or aluminum alloy coating. The welding blank is composed of a steel substrate and coatings comprising an intermetallic compound alloy layer contacting the substrate, and a metal alloy layer on the intermetallic compound alloy layer. On at least one of the coating surfaces of the welding blank, the coating within an area to be welded has been totally removed, and an end face of the coating on the side of the coating within the area to be welded removed has an angle of ? being 0-80° with a plane vertical to a surface of the substrate which is parallel to the welding seam. Also provided are welding methods for the steel welding component. The steel welding blank provided ensures the tensile strength, elongation, and corrosion resistance of a hot-stamped welded joint.

Abstract: A steel welding component with an aluminum or aluminum alloy coating, using a steel welding blank with an aluminum or aluminum alloy coating. The welding blank is composed of a steel substrate (1) and coatings (2, 2?); the coating (2) comprises an intermetallic compound alloy layer (21) which contacts the substrate (1), and a metal alloy layer (22) on the intermetallic compound alloy layer (21); on at least one of the coating surfaces of the welding blank, the coating (2) within an area (3) to be welded of the welding blank has been totally removed, and an end face (23) of the coating (2) on the side of the coating within the area (3) to be welded removed has an angle of ? with a plane vertical to a surface (11) of the substrate (1) which is parallel to the welding seam, wherein ? is 0-80°. Also provided are welding and preparation methods for the steel welding component.

Abstract: A resistance spot welding method of galvanized high-strength steel with good joint performance, wherein: three welding pulses are used within one spot welding schedule; a first welding pulse and a second welding pulse are used for generating a nugget and suppressing the generation of liquid metal embrittlement (LME) cracks, wherein the first welding pulse generates a nugget having a diameter of 3.75T½-4.25T½ in which T represents a plate thickness; the second welding pulse causes the nugget to grow slowly; and a third welding pulse which is a tempering pulse is used for improving plasticity of a welding spot. A time t1 of the first welding pulse is set and a welding current I1 of the first welding pulse is obtained through tests, and the welding current I1 of the first welding pulse is a welding current upon generating the nugget having the diameter of 3.75T½-4.